Text Size

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

This study has been terminated.
Sponsor:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00006187
First received: August 25, 2000
Last updated: December 10, 2009
Last verified: October 2003
History of Changes
  Purpose

This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.


Condition Intervention Phase
Alzheimer Disease
 Drug: Investigational drug
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Aging (NIA):

Estimated Study Completion Date: June 2005
Estimated Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Detailed Description:

This is a placebo-controlled, parallel-groups, 12 month, double-blind study, followed by a 3-month, double-blind, randomized withdrawal period to evaluate the efficacy and safety of an investigational drug (currently approved for other indications) to slow the progression of symptoms of AD. Patients with probable AD according to NINCDS-ADRDA criteria who have a Mini Mental State Examination (MMSE) score between 13 and 26 inclusive will be eligible for participation in the study.

Patients on stable doses of marketed cholinesterase inhibitors approved for the treatment of AD (except for tacrine) for at least 3 months are eligible for study entry. Use of NSAIDs (except aspirin 81 mg per day) is not allowed during the study.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is male or female and at least 50 years of age or older
  • Female patients must be postmenopausal or surgically sterilized
  • Clinical diagnosis of AD
  • Patient must be in good health except for AD diagnosis
  • Patient must have informant/caregiver who can monitor and assist patient during the study

Exclusion Criteria:

  • Patient is living in a nursing home or skilled nursing facility
  • Women will be ineligible if not postmenopausal or surgically sterilized
  • Site physician or Sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006187

  Show 34 Study Locations
Sponsors and Collaborators
Merck
Investigators
Principal Investigator: Klaus Beck, MD, PhD Merck
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00006187     History of Changes
Other Study ID Numbers: IA0025
Study First Received: August 25, 2000
Last Updated: December 10, 2009
Health Authority: Unspecified

Keywords provided by National Institute on Aging (NIA):
Investigational Drug

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 22, 2013